Alacris Theranostics

Executive Summary

Alacris Theranostics, a Berlin-based systems medicine company founded in 2015, is positioned at the intersection of oncology, diagnostics, and AI/ML. The company provides comprehensive next-generation sequencing (NGS) services and bioinformatics solutions, enabling researchers, pharmaceutical companies, and clinicians to derive actionable genomic insights. By integrating multi-modal NGS technologies, Alacris aims to accelerate precision medicine and improve therapeutic outcomes in oncology. Despite being privately held with limited public financial data, the company's focus on AI-driven genomic analysis aligns with the growing demand for personalized cancer care. As the precision oncology market expands, Alacris stands to benefit from increased adoption of NGS-based diagnostics and bioinformatics tools. Key upcoming catalysts include the launch of an enhanced AI-powered analysis platform, potential strategic partnerships with pharma players for clinical trial support, and expansion of its service portfolio into new cancer indications. These developments could drive revenue growth and solidify Alacris's position in the European precision medicine landscape.

Upcoming Catalysts (preview)

• Q3 2026Launch of AI-Powered NGS Analysis Platform70% success
• Q2 2026Strategic Partnership with Pharmaceutical Company for Clinical Trial Genomics50% success
• Q4 2026Expansion into New Oncology Indications60% success